Statins in Heart Failure—Where Do We Stand?

Author： Lyons Kristopher   McVeigh Gary   Harbinson Mark  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.25, Iss.1, 2011-02, pp. : 99-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intelligent use of NSAIDs - where do we stand?

By Berger R.G.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 19-30

Informa Healthcare

Access to resources Recommend Favorite

Mucosal Vaccines: Where Do We Stand?

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 20, 2013-10 ,pp. : 2609-2628

Bentham Science Publishers

Access to resources Recommend Favorite

Protease inhibitors - where do we stand?

By Neumann U.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 8, 2002-08 ,pp. : 394-394

Elsevier

Access to resources Recommend Favorite

Accelerated Partial Breast Irradiation: Where Do We Stand?

By Dirbas Frederick M.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 2, 2009-02 ,pp. : 215-225

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Granulocyte mobilization, collection and transfusion – where do we stand?

By MOOG RAINER  

Transfusion Alternatives in Transfusion Medicine, Vol. 11, Iss. 2, 2010-06 ,pp. : 65-71

Blackwell Publishing

Access to resources Recommend Favorite